Drug Combination Disappoints in Advanced NSCLC ...Middle East

Medscape - News
Second-line bevacizumab plus osimertinib showed some PFS benefit over osimertinib alone in a subset of smokers/former smokers but overall showed no survival benefits in the ETOP BOOSTER trial. Medscape Medical News

Hence then, the article about drug combination disappoints in advanced nsclc was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Drug Combination Disappoints in Advanced NSCLC )

Apple Storegoogle play

Last updated :

Also on site :